8-K: Avanos Medical Reports Positive First Quarter 2024 Results Driven by Digestive Health Growth

Avanos Medical, Inc. announced a 4.3% increase in net sales and a return to profitability in the first quarter of 2024, driven by strong performance in its Digestive Health segment.

Summary

• Avanos Medical reported a 4.3% increase in net sales from continuing operations, reaching $166.1 million in the first quarter of 2024.
• The company achieved net income from continuing operations of $0.5 million, a significant improvement from a net loss of $7.8 million in the same period last year.
• Adjusted net income from continuing operations was $10.1 million, compared to $6.0 million in the prior year.
• Adjusted EBITDA increased to $21.6 million, up from $16.1 million year-over-year.
• Diluted earnings per share from continuing operations was $0.01, compared to a loss of $0.17 per share last year.
• Adjusted diluted earnings per share from continuing operations was $0.22, compared to $0.13 a year ago.
• The Digestive Health portfolio saw strong demand, particularly for NeoMed neonatal and pediatric feeding solutions.
• The Pain Management and Recovery portfolio also experienced favorable volume growth, driven by Game Ready and Diros products, although slightly offset by unfavorable pricing.
• The company's cash balance at the end of the quarter was $75.8 million, down from $87.7 million at the end of 2023.
• Total debt outstanding was $176.6 million at the end of the quarter, compared to $168.0 million at the end of 2023.
• The company anticipates full-year revenue between $685 million and $705 million, adjusted gross margins between 59.5% and 60.5%, and adjusted diluted earnings per share between $1.30 and $1.45.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with improved financial results and growth in key segments. However, there are some concerns regarding cash flow and debt levels, which temper the overall sentiment.

Positives

• The company achieved a return to profitability in the first quarter of 2024.
• Net sales increased by 4.3% year-over-year, indicating strong demand for their products.
• Adjusted EBITDA and adjusted diluted earnings per share showed significant improvements.
• The Digestive Health segment demonstrated strong growth, particularly in neonatal and pediatric feeding solutions.
• The Pain Management and Recovery segment experienced favorable volume growth.
• Selling and general expenses decreased as a percentage of net sales, indicating improved cost management.
• The company is making progress on its long-term margin expansion targets.
• The company is delivering on its Digestive Health growth objectives.

Negatives

• Free cash flow was an outflow of $12.1 million, compared to an outflow of $10.8 million in the prior year.
• The company's cash balance decreased to $75.8 million from $87.7 million at the end of 2023.
• Total debt increased to $176.6 million from $168.0 million at the end of 2023.
• Gross profit margin decreased slightly due to costs related to the Transformation Process and plant separation costs.
• There was slightly unfavorable pricing for Pain Management and Recovery products.

Risks

• The company faces risks related to economic conditions that could affect demand for their products.
• Pricing pressures and cost-containment measures could impact the price of or demand for their products.
• Supply chain disruptions, including shortages in drugs used in Surgical Pain and Recovery products, could pose a risk.
• Ongoing regional conflicts could impact the company's operations.
• The company's ability to successfully execute on its transformation initiative is a risk.
• Inflationary pressures and financial conditions affecting the banking system could pose challenges.
• Changes in foreign exchange markets could impact financial results.
• Legislative and regulatory actions could affect the company.
• Unanticipated issues arising in connection with clinical studies and FDA approval of new products could pose a risk.
• Changes in reimbursement levels from third-party payors could impact revenue.
• A significant increase in product liability claims could pose a risk.
• The impact of investigative and legal proceedings and compliance risks could affect the company.
• Changes in financial markets and the competitive environment could pose challenges.

Future Outlook

The company anticipates full-year revenue between $685 million and $705 million from continuing operations, adjusted gross margins between 59.5% and 60.5%, and adjusted diluted earnings per share from continuing operations of between $1.30 and $1.45 for the year.

Management Comments

• Joe Woody, Avanos' chief executive officer, stated that they are pleased with the first quarter results as they begin the second year of their three-year transformation initiative.
• Woody added that they continue to make progress on their long-term margin expansion targets, are delivering on their Digestive Health growth objectives, and have made improvements in their Pain Management and Recovery franchise that will support mid-single digit growth in the back half of the year.

Industry Context

The results indicate a positive trend for Avanos Medical, particularly in the Digestive Health sector, which aligns with the growing demand for specialized medical solutions in this area. The company's focus on margin expansion and operational improvements also reflects a broader industry trend towards efficiency and profitability.

Comparison to Industry Standards

• Avanos' 4.3% revenue growth is a positive sign, but it is important to compare this to peers like Medtronic or Boston Scientific, which often report higher growth rates in certain segments.
• The adjusted EBITDA of $21.6 million is a significant improvement, but it is crucial to benchmark this against companies with similar market caps and product portfolios, such as Conmed or Nuvasive.
• The adjusted gross margin of 59.8% is competitive, but companies like Stryker or Johnson & Johnson often achieve higher margins due to their scale and product mix.
• The company's focus on transformation and restructuring is similar to what many medical device companies are doing to improve efficiency and profitability, but the success of these initiatives will be key to long-term performance.
• The free cash flow outflow of $12.1 million is a concern and needs to be monitored against industry benchmarks, as many medical device companies aim for positive free cash flow.

Stakeholder Impact

• Shareholders will likely view the improved financial results positively.
• Employees may benefit from the company's improved performance and growth.
• Customers will continue to receive the company's products and services.
• Suppliers will continue to engage with the company.
• Creditors will monitor the company's debt levels and financial performance.

Next Steps

• The company will continue to execute on its three-year transformation initiative.
• Avanos will focus on achieving its full-year revenue and earnings guidance.
• The company will continue to monitor and manage its cash flow and debt levels.

Key Dates

Keywords

Avanos Medical, Medical Technology, Digestive Health, Pain Management, Recovery, Net Sales, EBITDA, Earnings Per Share, Financial Results, Healthcare